EDGEWISE THERAPEUTICS INC
Edgewise Therapeutics (EWTX) is a clinical‑stage biopharmaceutical company developing oral small‑molecule therapies aimed at improving muscle function in neuromuscular and rare muscle disorders. With a market capitalisation of around $1.63bn, the business is largely valued on the progress of its pipeline and clinical data rather than current revenues. Investors should note the typical biotech risk profile: trial results, regulatory decisions and funding needs can drive significant share price movement. Edgewise's prospects depend on scientific proof of concept, safety outcomes and the company’s ability to fund development through pivotal studies. This summary is for educational purposes only and does not constitute personal investment advice. Consider suitability, diversification and your own risk tolerance before considering exposure to clinical‑stage biotechnology companies, as values can rise or fall and past performance is not a reliable indicator of future results.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Edgewise Therapeutics' stock with a target price of $38.17, indicating strong growth potential.
Financial Health
Edgewise Therapeutics is performing well with solid cash flow and a strong book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring EWTX
Gene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline growth potential
Edgewise’s valuation is closely tied to clinical data; positive trial readouts could change outlook, though biotech results are uncertain and can disappoint.
Rare disease focus
Targeting rare and genetically defined muscle disorders can offer clearer regulatory paths and distinct patient needs, yet market size and reimbursement remain considerations.
Upcoming clinical catalysts
Near‑term study readouts and regulatory interactions may act as catalysts, while financing and safety outcomes are additional variables to watch.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
